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Abstract
Blast-phase chronic myeloid leukemia (BP-CML) is associated with additional chromosomal aberrations, RUNX1 mutations
being one of the most common. Tyrosine kinase inhibitor therapy has only limited efficacy in BP-CML, and characterization of
more defined molecular subtypes is warranted in order to design better treatment modalities for this poor prognosis patient group.
Using whole-exome and RNA sequencing we demonstrate that PHF6 and BCORL1mutations, IKZF1 deletions, and AID/RAG-
mediated rearrangements are enriched in RUNX1mut BP-CML leading to typical mutational signature. On transcriptional level
interferon and TNF signaling were deregulated in primary RUNX1mut CML cells and stem cell and B-lymphoid factors
upregulated giving a rise to distinct phenotype. This was accompanied with the sensitivity of RUNX1mut blasts to CD19-CAR
T cells in ex vivo assays. High-throughput drug sensitivity and resistance testing revealed leukemia cells from RUNX1mut
patients to be highly responsive for mTOR-, BCL2-, and VEGFR inhibitors and glucocorticoids. These findings were further
investigated and confirmed in CRISPR/Cas9-edited homozygous RUNX1−/− and heterozygous RUNX1−/mut BCR-ABL positive
cell lines. Overall, our study provides insights into the pathogenic role of RUNX1 mutations and highlights personalized targeted
therapy and CAR T-cell immunotherapy as potentially promising strategies for treating RUNX1mut BP-CML patients.
Introduction
RUNX1, also known as core binding factor subunit alpha
(CBFA2), is a transcription factor (TF) and an essential
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component of the core binding factor complex that plays a
key role in hematopoiesis [1]. Somatic and germline
alterations involving RUNX1 gene are commonly encoun-
tered in a variety of hematological malignancies [2].
RUNX1 germline mutations are associated with familial
platelet disorders (FPD) with predisposition to hematolo-
gical malignancies [3]. In acute leukemia, RUNX1 is
affected by a range of chromosomal rearrangements
resulting in fusions with multiple partners [4]. These
include t(8;21) RUNX1-RUNX1T1 translocation in 15% of
AML patients [5], t(12;21) ETV6-RUNX1 translocation in
25% of BCP-ALL patients [6], and t(3;21) RUNX1-
MECOM in therapy-related MDS/AML patients [7]. In the
t(12;21) ETV6-RUNX1 ALL, it has been reported that the
aberrant RAG recombination activity mediates off-target
deletions and is the driver mutagenic mechanism [8]. In
normal physiology, activation-induced cytidine deaminase
(AID)/RAG axis is important in V(D)J rearrangement and
somatic hypermutation (SHM) process during B lympho-
cyte development [9, 10].
Somatic RUNX1 mutations are frequent among hemato-
logical malignancies like AML [11], ALL [12], MDS [13],
and MDS/MPN (CMML) [14]. AML with mutated RUNX1
(RUNX1mut AML) is a provisional entity which accounts for
10% of the newly diagnosed patients and associates with an
inferior prognosis [11, 15]. RUNX1 mutations are frequently
encountered in AML patients with minimal differentiation
(AML-M0), where it demonstrates a unique molecular
signature with upregulation of B-lymphoid genes [16].
Aberrant expression of the lymphoid marker CD19 is fre-
quently observed in t(8;21)-AML [17], representing an
interesting target for immunotherapy [18]. RUNX1mut AML
shows associations with mutations affecting spliceosome
(SRSF2 and SF3B1), epigenetic modifiers (ASXL1 and
EZH2), and PHF6 and BCOR genes [19, 20]. Furthermore,
FLT3-ITD and MLL-PTD frequently coexist with RUNX1
mutations, while fusion genes and NPM1 mutations are
mutually exclusive with RUNX1 mutations [21].
RUNX1 mutations have also been found in CML
patients and linked to disease progression and inferior
treatment responses [22–24]. In our previous study,
RUNX1 mutations were identified as recurrent events in
BP-CML (3 out of 20 patients) [25]. In concord, functional
studies in mice have shown that RUNX1 mutations can
contribute to blast transformation of CML [26, 27].
Nevertheless, little is known about the role of RUNX1
mutations in BP-CML. We therefore investigated the
mutational profiles of RUNX1-mutated (RUNX1mut) and
wild-type (RUNX1wt) BP-CML patients with whole-exome
and RNA sequencing and integrated public genomic data
of BP-CML patients to increase accuracy. This approach
allowed us to enlighten a novel mutagenesis role of
RUNX1 mutations that is coupled with the activation of
AID/RAG axis. Gene expression profiling demonstrated
characteristic transcriptional programming in RUNX1mut
cases including upregulation of stem cell and B-lymphoid
genes. Using drug sensitivity profiling of primary leuke-
mia cells and CRISPR/Cas9 RUNX1 gene-edited CML cell
lines, we identified novel effective targeted therapies and
CD19-CAR T cells as a promising immunotherapeutic
option. Our data provide a comprehensive genomic and
functional characterization of RUNX1mut BP-CML.
Materials and methods
Patients
Clinical and hematological features of BP-CML patients are
summarized in Supplementary Table 1. CML diagnosis and
progression were defined according to World Health
Organization criteria [28]. All subjects gave their written
informed consent in accordance with the declaration of
Helsinki. In addition, we integrated whole-exome and
RNA-sequencing data from previously published BP-CML
patients [24].
Cell lines
Baf3 cells transfected with P210-BCR-ABL1-GFP were a
gift from Prof. Nikolas von Bubnoff, Universitätsklinikum
Freiburg, Germany. K562 was obtained from DSMZ
(German Collection of Microorganisms and Cell Cultures).
Both cell lines were cultured in RPMI-1640 (Lonza) sup-
plemented with 10% FBS, 2-mM L-glutamine (Lonza), and
100-U/mL penicillin and 100-μg/mL streptomycin (Gibco).
Flow cytometry analysis
Patient samples (bone marrow mononuclear cells (BMNCs))
and cell lines were stained with relevant panels of antibodies
as indicated in the Supplementary materials, using recom-
mended manufacturer protocols for surface antibodies stain-
ing. Cells were acquired with the FACS Verse and analyzed
with FlowJo software (Version10.0.8r1, TreeStar). All anti-
bodies were purchased from BD Biosciences, San Diego,
CA, USA.
Whole-exome sequencing (WES), RNA sequencing,
and data analysis
Genomic DNA was extracted from BP-CML patients’
BMNCs. Skin samples were collected and used as
germline controls to identify somatic mutations. WES
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protocol has been described in the earlier study [25]. The
mean coverage depth was 138× (range: 99.9×−168.4×)
(Supplementary Table 1). Regarding RNA sequencing,
RNA isolation and RNA-sequencing protocol have been
described earlier [25]. Details of RNA-sequencing work-
flow, bioinformatics analysis, and adjustment for possible
confounding factors are described in Supplementary
materials.
Drug sensitivity and resistance testing (DSRT)
The oncology compounds library, employed to test patient
samples, consisted of 125 FDA/EMA anticancer approved
drugs and 127 investigational and preclinical compounds.
For cell lines, a comprehensive library of 528 compounds
(156 approved drugs and 372 investigational compounds)
was used. Drugs were tested in five increasing concentra-
tions over a 10,000-fold range. For drug combination test-
ing, the selected drugs were tested with dose–response
matrices comprising seven different concentrations. DSRT
was performed as previously described [29], and quantifi-
cation of DSS and drug synergy scores is described in
Supplementary materials.
CRISPR/Cas9 RUNX1 gene editing
Baf3-BCR-ABL1 cells were transfected with pU6-(BbsI)-
CBh-Cas9-T2A-mCherry (Addgene plasmid#64324) expres-
sing CRISPR-Cas9 and sgRNA targeting exon-4 of runx1
gene using Fugene HD transfection reagent (Promega). All of
sgRNA, primers, oligos, plasmids, and antibodies are listed in
Supplementary Table 2. Selection of clones and validation of
editing is described in Supplementary materials.
Generation of and phenotyping of CAR T cells and
ex vivo CAR T cells cytotoxicity assay
CAR T cells were manufactured and the ex vivo cytotoxi-
city assay was performed as previously described [30, 31]
and indicated in the Supplementary methods. The cells were
stained using a designed antibodies panel (Supplementary
Table 3). Cells were acquired using iQue Screener Plus flow
cytometer and analyzed using the ForeCyt software (edition
6.2, Intellicyt). Details of data analysis can be found in
Supplementary materials.
Statistical analysis
Two-tailed Student t test, Mann–Whitney U-test, Fisher
Exact test, Spearman correlation, Pearson’ correlation tests,
and Fisher’s Exact Test with simulated p value on 1e+ 07
replicates were computed using GraphPad Prism 7 software
or R 3.5.0.
Results
RUNX1 mutations are frequent in BP-CML and
co-occur with IKZF1 deletions and PHF6 and BCORL1
mutations
We analyzed thirteen samples from eight BP-CML patients
with a median age of 45 years (range 24–74 years) using
WES (Supplementary Table 1). Serial samples were avail-
able for four patients either from diagnostic CP-CML (n=
1), relapse (n= 2), or both (n= 1). In our WES cohort
(marked with Awad et al. in the Fig. 1a and Supplementary
Fig. 1a), four patients harbored somatic mutations in the
RUNX1 gene. RUNX1 mutations included three missense
mutations (p.R162K, p.R204Q, and p.R107C) and one
nonsense mutation (p.K117*), that were all located in the
Runt domain (Fig. 1b). Myeloid BP and lymphoid BP were
nearly evenly distributed between RUNX1mut and RUNX1wt
groups (p > 0.99, Fig. 1a). Blasts from myeloid-BP
RUNX1mut patients frequently expressed HLA-DR, TdT,
and aberrant lymphoid markers (CD19 or CD7 in two out
three myeloid RUNX1mut BP patients) (Supplementary
Table 1). RUNX1mut BP-CML patients showed a notable
population of plasmacytoid dendritic cells (pDCs) in con-
trast to RUNX1wt group (Supplementary Fig. 1b).
To enable comprehensive profiling of the mutational
landscape of RUNX1mut BP-CML patients, we reanalyzed
WES data from Branford et al. publication [24]. We
recovered four RUNX1 mutations (p.T176fs, p.L175Q,
p.D198G, c.508+2T>C splice donor) in three patients
(Supplementary Table 4). We also supplemented the data
with Grossman et al. publication [22] in which targeted
sequencing approach had been used. Frequent co-occuring
mutations in RUNX1mut patients included PHF6 and
BCORL1 mutations (Fig. 1a, Supplementary Fig. 1a, and
Supplementary Table 4). IKZF1 deletions were more com-
mon in RUNX1mut patients, but also found in lymphoid
RUNX1wt BP-CML patients (Fig. 1a). In mut2 patient with
longitudinal samples, a RUNX1 mutation (p.R162K) was
seen also in diagnosis (CP) sample (variant allele frequency,
VAF= 58%), with acquisition of loss of heterozygosity and
loss of the wild-type allele prior sampling at BP (VAF=
99%) (Supplementary Fig. 1c).
RUNX1 mutations confer a distinct mutational
signature with characteristic AID/RAG-mediated
activity
To elucidate the active mutational processes in BP-CML
patients, we performed mutational signature analysis of the
called variants. Age-related signature, DNA double-strand
break repair, and DNA mismatch repair signatures revealed
notable contribution to the mutational profile of BP-CML
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patients (Fig. 2a). Signature-9 was prominent in RUNX1mut
samples, including myeloid-BP RUNX1mut, but absent in
RUNX1wt samples. Signature-9 is related to AID/RAG
activity and polymerase η-induced SHM [32]. Notably,
several AID/RAG components, including RAG1, RAG2,
AICDA, and DNTT genes, were overexpressed in RUNX1mut
compared with RUNX1wt patients (Fig. 2b). Extension of
the analysis to the combined data of 20 BP-CML patients
(RUNX1mut; n= 7, RUNX1wt; n= 13) showed no significant
differences in the mutational load or structural variants
(SV) between RUNX1mut and RUNX1wt patient samples
(Supplementary Fig. 2a–c and Supplementary Table 5).
Mutational signature profiles of RUNX1mut patients from
both cohorts showed significant similarity (Supplementary
Fig. 2d and Supplementary Table 6), and SHM signature-9
demonstrated enrichment in RUNX1mut patients’ profile
exclusively also in the combined dataset (Fig. 2c).
Given the enrichment of SHM signature-9 in mutation
profiles of RUNX1mut cases, an unsupervised motif search
algorithm was used to explore contribution of AID/RAG-
mediated recombination events to SV events. We first
analyzed the 20-bp sequence spanning the breakpoint.
The perfect heptamer sequence CACAGTG was sig-
nificantly enriched in RUNX1mut patients compared with
RUNX1wt group (p < 0.01). RAG heptamer was demon-
strated in 31 sites involving one or both ends of 23/32 (71.9%)
of breakpoints in RUNX1mut patients (E value= 1.7 × 10–14)
compared with 20 sites involving 16/39 (41%) of breakpoints
in RUNX1wt patients (Fig. 2e). By increasing the size of th-
e output motif, the RAG canonical RSS motif (conserved
heptamer (CACAGTG) and nonamer (ACAAAAACC)
separated by a 12-bp spacer) was only enriched around
breakpoints in RUNX1mut patients (16 sites involving 12/32
(37.5%) of breakpoints, E value= 8.0 × 10–46) (Fig. 2f and
Supplementary Fig. 3). Interestingly, we observed RAG-RSS
at both ends of an intragenic IKZF1 deletion in a RUNX1mut
patient.
RUNX1 mutations induce upregulation of stem cell
and B-lymphoid markers, interferon signaling, and
immune-related pathways
To gain insights into the transcriptional changes induced by
RUNX1 mutations, diagnostic samples from four RUNX1mut
and five RUNX1wt patients, were analyzed using RNA-
sequencing (Fig. 3a). After adjusting for possible con-
founding factors, we identified 396 genes that were differ-
entially expressed between RUNX1mut and RUNX1wt
patients (Q < 0.05, Supplementary Table 7). Distinct phe-
notypic markers and TFs, including genes associated with
hematopoietic stem cells (HSC) (CD133/PROM1, BAALC,




Fig. 1 Spectrum of RUNX1 mutations in BP-CML patients. a
Landscape of somatic mutations identified by WES in BP-CML
samples from our cohort (n= 8, 4 RUNX1mut and 4 RUNX1wt) and
from Branford et al. [24] (n= 12, 3 RUNX1mut and 9 RUNX1wt).
Complete lists of identified mutations are detailed in Supplementary
Table 4. Explanatory tracks from top to bottom show phenotype of the
blast (myeloid-BP, lymphoid-BP, and Ambiguous) and phase of CML
(accelerated phase AP or blast phase BP) cases. The filling color
indicates the type of the variant. The average expression of the genes
in 4 RUNX1mut (red) and 5 RUNX1wt (blue) BP-CML samples is
shown on the right expressed as counts per million mapped reads
(CPMs). Bar lengths indicate means and errors. Chromosomal
abnormalities, including recurrent abnormalities and high-risk leuke-
mia-associated abnormalities, are shown in the lower part of the plot.
The bottom explanatory track indicates the study cohort. b Schematic
diagram of the protein structure and domains of RUNX1 protein and
position of mutations in BP-CML. RUNT domain (85–206), TAD
(318–389), and RunxI (389–480). Each diamond represents one call of
the variant and the fill color represents the type/predicted change of the
variants. Diamonds in the upper panel represent variants detected in
this study and diamonds in the lower panel represent RUNX1 variants
previously called in published BP-CML data [22, 24] (see also Sup-
plementary Fig. 1a).
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PAX5, CD19) were upregulated, whereas markers of
megakaryopoiesis, erythropoiesis, and granulopoiesis
(ITG3B/CD61, PF4, ABO) were downregulated in
RUNX1mut patients (Fig. 3a–c and Supplementary Fig. 4).
pDCs-specific TFs, including IRF8 and TCF4, were simi-
larly upregulated in RUNX1mut patients. RUNX1 mutations
were associated with dysregulation of several immune
regulatory molecules, including CIITA, CD74, B7-H6
(NCR3LG1), CD69, and multiple HLA-DR and TLR mole-
cules, in addition to cytokine receptors (IL2RA, IL21R, and
IL12RB2) (Fig. 3a–c and Supplementary Fig. 4).
Results from gene set enrichment analysis (GSEA)
showed upregulation of interferon alpha and gamma sig-
naling, antigen processing and presentation, TNF and
MAPK signaling pathways in RUNX1mut patients, whereas
coagulation and complement pathways were the most
downregulated (Fig. 3d, e). RUNX1mut upregulated gene
sets were enriched for HSC-specific pathways while
differentiation-related (neutrophil-related) pathways were
enriched in the downregulated sets. Expression profile of
RUNX1mut BP-CML patients shared similarities with CBF-
related AML in contrast with NPM1mut-AML and AML
with granulocytic or megakaryocytic differentiation (Sup-
plementary Table 7).
Since our cohort had a dominance of myeloid-BP phe-
notype (6/9 patients), we investigated whether RUNX1mut-
induced transcriptional changes can also be demonstrated in
lymphoid-BP phenotype. We analyzed data of lymphoid-
BP patients from Branford et al. [24] (n= 16 patients,
RUNX1mut= 7, RUNX1wt= 9). Lymphoid-BP samples
showed clustering according to RUNX1 mutation status.
Upregulation of several genes, including BAALC, CD133,
ST18, and FLT4, was comparable to RUNX1mut myeloid-BP
profiles. Furthermore, GSEA demonstrated similarities of
upregulated pathways between RUNX1mut lymphoid-BP
and CBF-related AML in contrast to NPM1mut-AML,










































































































































Signature 15 (DNA MMR)
Signature 9 (SHM)
Signature 3 (DNA DSBR)
Signature 1 (age-related)
others
Fig. 2 Cancer signatures and mutation loads of RUNX1mut patients
highlight the contribution of AID/RAG pathway to mutagenesis.
a Normalized weights of trinucleotide signatures in four RUNX1mut BP
and four RUNX1wt patients highlighted the major contribution of
signature-9 (related to AID/RAG pathway) in RUNX1mut BP patients.
Weights of the three most frequent signatures (if applicable) in each
cancer type are shown across cancers as separate signatures. Total
weight of all other signatures is shown under the category “other.” b
Expression levels (CPM log2 values) of RAG1, RAG2, and DNTT
genes are significantly higher in RUNX1mut patients compared with
RUNX1wt patients (*p < 0.05, **p < 0.01, ***p < 0.005, two-tailed
student’s test). c Normalized weights of trinucleotide signatures from
combined data including 7 RUNX1mut and 13 RUNX1wt BP-CML
patients underscored the association of signature-9 with RUNX1mut in
BP-CML patients. Weights of the three most frequent signatures in
each cancer type are shown across cancers as separate signatures. Total
weight of all other signatures is shown under the category “other.”
d RAG-RSS heptamer sequence identified by agnostic motif search
using MEME in 23/32 breakpoints in RUNX1mut BP (E value= 1.7 ×
10–14) and in 16/39 breakpoints in RUNX1wt patients (E value= 1.4 ×
10–14) within 20 bp of breakpoint junctions. e RAG canonical RSS,
heptamer, and nanomer sequences (in boxes) separated by 12-bp
spacer, identified by agnostic motif search using MEME in 16/32
breakpoints in RUNX1mut BP within 100 bp of breakpoint junctions
(E value= 8.0 × 10–46).
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RUNX1mut BP-CML cells showed increased
sensitivities to mTOR, VEGFR, BCL2 inhibitors,
and glucocorticoids
Next, we explored how the RUNX1 mutation-induced geno-
mic changes modulate the drug responses of BP-CML cells.
DSS were quantified for a panel of 255 oncology drugs using
cells from eight BP-CML patients (Supplementary Table 8).
Compared with RUNX1wt, RUNX1mut patients showed greater
sensitivity to mTOR inhibitors, VEGFR inhibitors, gluco-
corticoids, and navitoclax (Fig. 4a, b and Supplementary
Fig. 6a). This selective activity was more notable when lim-
iting the comparison to patients with myeloid-BP CML
(Supplementary Fig. 6b, c). Overexpression of genes encod-
ing targets for some of the identified drugs was observed in
the RUNX1mut-associated transcriptional data, including
NR3C1 gene (glucocorticoid receptor) and FLT4 gene
(VEGFR3 receptor) (Supplementary Fig. 6d). Interestingly,
cells from a patient with nonsense RUNX1 mutation
demonstrated enhanced sensitivity to glucocorticoids and
mTOR inhibitors and reduced sensitivity to navitoclax,
compared with those with RUNX1 missense mutations (two
patients) (Supplementary Fig. 6e).
Given the ex vivo effectiveness of the selected drugs, we
tested whether the combination of these drugs with a TKI
would enhance killing of RUNX1mut blasts in the ex vivo
setting. We tested cells from the RUNX1mut (n= 4) and
RUNX1wt (n= 2) patients with imatinib in combination with
dexamethasone, everolimus, cobimetinib, axitinib as well as
venetoclax in a dose-dependent manner to investigate
potential synergistic drug activities (Supplementary Fig. 7
and Supplementary Table 8). One patient carried gatekeeper
ABL1-T315I resistance mutation, hence imatinib was not
active and no synergy was detected (Fig. 4c). In RUNX1mut
patients, we were able to identify specific potential syner-
gistic effects of imatinib-dexamethasone combination and
to a lesser degree, imatinib-cobimetinib and imatinib-
venetoclax combinations (Supplementary Fig. 7).
Fig. 3 Transcriptional profiling of BP-CML patients demonstrate
upregulation of stem cell and lymphoid markers, interferon
signaling, and dysregulation of immune-related pathways in
RUNX1mut BP-CML patients. a Heatmap of top statistically differ-
entially expressed genes (Q < 0.05, two-tailed student’s test) correlat-
ing with RUNX1 mutations with absolute logFC > 3. Fading blue
colors indicate downregulation of the gene in the sample and red its
upregulation relative to the mean expression of the genes across all
samples. Explanatory tracks from top to bottom show RUNX1 status,
blast phenotype, and mutation type. Clustering was performed for both
genes and samples using the Euclidean distance and Ward linkage
method. b Correlation of expression levels of all protein-coding genes
between RUNX1mut and RUNX1wt subsets. Each gene is represented by
a gray dot. Significantly differentially expressed genes (Bayesian
statistical test, Q < 0.05) are represented by black triangles. Red and
blue squares represent the top 50 upregulated and downregulated
genes, respectively (Pearson correlation R2= 0.88). c Volcano plot of
protein-coding genes between RUNX1mut (right) and RUNX1wt (left).
Each gene is represented by a black dot, and significant differentially
expressed genes (Q < 0.05, Bayesian statistical test) are colored red.
d GSEA of TNF, IFN-alpha, IFN-gamma, and CBF-AML pathways
upregulated in RUNX1mut compared with RUNX1wt patients. e GSEA
of coagulation, complement, NPM1mut-AML, and AML-FAB M7
pathways downregulated in RUNX1mut compared with RUNX1wt
patients.
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In CML cell lines, RUNX1 mutations induce
phenotypic, transcriptional, and drug sensitivity
profiles similar to RUNX1mut BP-CML patients
Given the complex genetic background of BP-CML patients,
we next validated whether the identified transcriptional and
drug sensitivity characteristics are truly specific to RUNX1
mutations. We used a mouse Ba/f3 cell line transduced with
P210-BCR-ABL1 expression vector as a model of CP-CML
to simulate the impact of RUNX1 mutations on the disease
phenotype. We created a RUNX1−/− cell line with complete
RUNX1 knockdown (homozygous deletion) and a RUNX1−/mut
cell line with an in-frame deletion (−3), predicted to have a
deleterious effect on protein function, together with an out
of frame (−1) deletion (heterozygous deletion) using
CRISPR-cas9 technology, that was validated using western
blot of RUNX1 protein (Fig. 5a and Supplementary Fig. 8a, b).
Phenotypic analysis showed an induced expression of CD19 in
RUNX1−/mut cell line, but neither in RUNX1−/− line, wild-type
control line (RUNX1wt/wt) nor parental cell line (Fig. 5b). RNA
sequencing of the CRISPR-edited cell lines demonstrated
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Fig. 4 Drug response pattern characteristic of RUNX1mut BP-CML
patients. a Scatter plot comparing drug sensitivity score (DSS) of
RUNX1mut (n= 4) and RUNX1wt BP-CML patients (n= 4). Color
indicates different drug families (primary targets). b The top 20 tar-
geted compounds with selective activity across RUNX1mut BP-CML
patient compared with RUNX1wt BP-CML patient samples ranked by
the difference of the median DSS scores between RUNX1mut and
RUNX1wt groups, i.e., differential drug sensitivity score (dDSS).
Conventional chemotherapeutic drugs (Supplementary Table 8) and
broadly active compounds (CUDC-907, KX2–391, UCN-01, ONX-
0914) are excluded. c Heatmap showing the highest single agent
(HSA) synergy score when combining imatinib with each of the
selected drugs (everolimus, axitinib, cobimetinib, venetoclax, dex-
amethasone) in four RUNX1mut BP-CML patients (top panel). An
example is highlighted that shows an increased potency of imatinib
(decreased IC50) with increased dexamethasone concentrations (middle
panel) and the corresponding HSA synergy plot of the imatinib-
dexamethasone combination (bottom panel), showing synergy dis-
tribution and the most synergetic concentration window (dotted area).
Asterisk indicates mut1 patient carrying gatekeeper ABL1-T315I
resistance mutation. A full set of the synergy plots for all the combi-
nations can be found in Supplementary Fig. 7.
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pathways in the downregulated gene sets in RUNX1−/− line,
compared with wild-type control line. The transcriptional pro-
file of the RUNX1−/mut cell line shared many similarities with
RUNX1mut BP-CML patient profiles (Supplementary Table 9).
Interferon signaling, inflammatory response, and antigen pre-
sentation pathways were upregulated while neutrophil degra-
nulation and differentiation pathways were downregulated
(Fig. 5c).
Next, we compared the drug sensitivity profiles of
RUNX1-edited cell lines. RUNX1−/mut showed higher sen-
sitivity to mTOR-, VEGFR- and CDK- inhibitors in
agreement with patient DSRT profiles. In addition,
RUNX1−/mut demonstrated selective resistance to IAPs
inhibitors (NVP-LCL-161, birinapant, and AT-406) and
BET inhibitors (JQ, birabresib, and I-BET151), which were
not tested in the patient samples (Fig. 5d, e and Supple-
mentary Table 10). In addition to Ba/f3 cell line, we also
created a K562-RUNX1−/− cell line, which showed similar
drug sensitivity profile (Supplementary Fig. 8c). Induced
re-expression of wild-type RUNX1 gene was able to restore
the sensitivity patterns of the parental cell line to the
selected compounds in RUNX1−/− but not in RUNX1−/mut
cells, confirming specificity of the induced DSRT changes
to the RUNX1 status (Fig. 5f). Furthermore, introduction of
RUNX1 p.R162K mutation in Baf3-BCR-ABL1 or K562 cell
lines induced changes in the sensitivity profiles, including
enhanced activity of navitoclax, AZD8055, and axitinib
similar to RUNX1mut patients’ profiles (Supplementary
Fig. 5 RUNX1 CRISPR-edited CML cell lines show transcriptional
reprogramming and DSRT profiles similar to changes in RUNX1-
mut BP-CML patients. a Western plot of RUNX1 protein confirm
efficient CRISPR-editing where RUNX1−/− cell line shows complete
loss of RUNX1 protein and RUNX1−/mut cell line reduction of RUNX1
protein level compared with control. b Flow cytometry plot of
CRISPR-edited and control cell lines. RUNX1−/mut cell line shows
induced phenotypic changes with expression of CD19 and CD11b in
contrast to RUNX1−/− and control lines. c Depiction of molecular
pathways with significant altered expression between RUNX1−/mut and
RUNX1wt/wt cell lines using the top differentially expressed genes with
>2 log foldchange (the top 300 upregulated and the top 300 down-
regulated genes). The red bars are upregulated pathways and blue bars
downregulated pathways. The analysis highlighted the reprogramming
of expression of genes similar to RUNX1-mut BP-CML patients’ pro-
files related to IFN, TNF, and antigen presentation pathways. Full lists
of differentially expressed genes and enriched pathways are listed in
Supplementary Table 9. d Correlation of DSS scores between RUNX1−/mut
and RUNX1wt/wt cell lines, highlighting acquired sensitivity to (AZD8055,
temsirolimus), MEK- (gedatolisib, cobimetinib), CDK- (SNS-032,
AT7519), BET- (JQ1, birabresib), and VEGFR- (axitinib) inhibitors and
resistance to XIAP inhibitors (NVP-LCL-161, AT-406).
e Correlation of DSS scores between RUNX1R162K (representing RUNX1
missense mutation) and RUNX1−/mut (representing RUNX1 nonsense
mutation) cell lines, highlighting differential activity of mTOR-, MEK-
inhibitors (more active in nonsense mutated line), and BCL2 inhibitor
(navitoclax is more active in missense mutated cell lines), similar to
patient-derived primary cells. f Comparison of drug responses of Baf3-
BCR-ABL1 CRISPR-edited (RUNX1−/−, RUNX1−/mut, RUNX1wt/wt) and
parental cell lines to selected active agents temsirolimus, AZD8055
(mTOR inhibitors), axitinib (VEGFR inhibitor), navitoclax (BCL2 inhi-
bitor), and NVP-LCL-161 (XIAP inhibitor). The bar height represents
DSS scores. R indicates induced re-expression of wild-type RUNX1 gene.
Acquired drug activities in RUNX1−/− line were lost with RUNX1 re-
expression (e.g., mTOR and VEGFR inhibitor differential activities), but
not in RUNX1−/mut cell line where the mutant RUNX1 is driving the drug
sensitivities (e.g., NVP-LCL-161 resistance).
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Fig. 8d, e). Interestingly, differential drug activity
associations with somatic mutation types (e.g., enhanced
mTOR activity with nonsense mutations and navitoclax
activity with missense mutations) were also notable in the
cell line models (Fig. 5e).
CD19-CAR T cells revealed potent ex vivo activity
against RUNX1mut BP-CML patient cells with an
additive effect to TKI inhibition
Given the RUNX1mut-associated distinct phenotype, namely
the aberrant expression of CD19 lymphoid marker in myeloid
blast cells, we investigated the potential use of CD19-CAR T-
cell immunotherapy in RUNX1mut BP-CML patients. We
tested the ex vivo cytotoxic activity of CD19-CAR T cells
against RUNX1mut BP-CML blasts (i.e., CD34-positive cells)
with and without imatinib using flow cytometry (Fig. 6a, b
and Supplementary Fig. 9a). CD19-CAR T cells showed a
potent activity against RUNX1mut BP-CML blasts in patients
expressing CD19 including one lymphoid-BP (mut1) and one
myeloid-BP patient (mut2) with aberrant CD19 expression on
25% of blasts. In a 24-h coculture experiment, CD19-CAR
T cells were able to induce killing of blasts at effector–target
(E–T) (CAR T cells: CD34+ cell) ratio as low as 1:8 at a
variable extent (13–50%). The demonstrated cytotoxic activ-
ity of CD19-CAR T cells was specific in contrast with mock-
CAR T cells (Fig. 6c). At an E–T ratio of 2:1, CD19-CAR T
cells-induced killing was superior to killing by imatinib (100
nM), not only in mut1 patient who carried ABL1-T315I
resistance mutation, but also in mut2 with no TKI-resistance
mutation. Combining CD19-CAR T cells with imatinib
showed an enhanced inhibitory effect compared with imatinib
alone, or imatinib with mock cells (10,000-fold concentration
range 1–10,000 nM) (Fig. 6d). Coculture of CD19-CAR
T cells with blasts induced strong CD8+ CAR T cells acti-
vation, as demonstrated by 1.5–4-folds increase in CD69





Fig. 6 Ex vivo CD19-CAR T-cell activity against RUNX1mut
BP-CML patient blasts. a Comparison of ex vivo activity of CD19-
CAR T cells, mock-CAR T cells, and imatinib (100 uM) and com-
bination of imatinib and CAR T cells in RUNX1mut BP-CML patients
(n= 4) after 24-h incubation (effector–target, E–T ratio 2:1). The
upper tags show RUNX1 mutations, BP phenotype, and percentage of
CD34+CD19+ out of blast cells. Bar height represent viability per-
centage. CD19-CAR T cells showed the highest activity in lymphoid-
BP patient (mut1) with T315I resistance mutation compared with
mock cells and imatinib. They also had comparable activity as imatinib
in myeloid-BP patients with more cytotoxic activity in patient mut2
with aberrant CD19 expression (20% of the cells). b Flow cytometry
plot showing the activities of imatinib (IM), mock and CD19-CAR
T cells (E–T ratio 2:1) on CD34+ blasts in two RUNX1mut BP-CML
patients (lymphoid BP (mut1) in the upper panel and myeloid BP
(mut2) with aberrant CD19 in the lower panel) after 24-h incubation.
Each plot is constructed by plotting 7-AAD expression on the X-axis
and CD34 on Y-axis, with the right gate showing dead cells (7-AAD
positive) and the left gate showing viable cells (7-AAD negative).
CD19-CAR T cells were capable of inducing potent killing of blasts in
both patients. c Comparison of mock and CD19-CAR T cells activities
using different E–T ratios in two BP-CML patients (mut1 and mut2).
CD19-CAR T cells at concentrations as low as 1:8 blasts were able to
induce blast killing. Non-specific killing activity by mock cells was
observed in ly-BP patient (mut1) but not in my-BP patient (mut2).
d Dose–response curves of imatinib in serial concentration (range
1–10000 μM, 5 concentrations) alone and in combination with mock
and CD19-CAR T cells (at 1:2 E–T ratio) in two BP patients after 24-h
incubation. Ly-BP (mut1) with T315I mutation showed resistance to
imatinib but potent activity to CD19-CAR T cells+ imatinib combi-
nation. In my-BP patient (mut2), CD19-CAR T cells showed additive
killing effect to imatinib at low imatinib concentrations.
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expression. On the other hand, a modest activation of CD4+
CAR T cells was observed, as well as a minimal non-specific
activation of mock-CAR T cells (Supplementary Fig. 9b).
In CD19-neg RUNX1-mutated patients (n= 2), CD19-
CAR T cells-induced cytotoxicity was modest, high-
lighting the specificity of CAR T cells activity (Fig. 6a
and Supplementary Fig. 10a). CD19-CAR T cells could
still induce variable killing effect on BP-CML blasts,
compared with mock-CAR T cells. Notably, in one
myeloid-BP patient (mut4), CD19-CAR T-cells-induced
cytotoxicity was superior to imatinib-induced inhibition
(Supplementary Fig. 10a–c). In RUNX1wt myeloid-BP
patients, no enhanced activity with imatinib was noted,
but cells from patient with CD19+ lymphoid-BP were
killed effectively by CD19+ CAR T cells (Supplementary
Fig. 10d).
Discussion
Several studies have linked CML progression to the accu-
mulation of somatic mutations and copy number changes
[23–25]. However, whether these additional genetic aberra-
tions define specific disease subtypes, which are still largely
uncharacterized. In this work, we systematically studied
the genomic, transcriptional, and drug sensitivity profiles
of BP-CML primary patient samples with and without
RUNX1 mutations. Our study coupled RUNX1 mutations in
BP-CML with recombination events caused by off-target
activity of AID/RAG complex. To our knowledge, this is the
first such report in myeloid malignancies. Our results also
highlighted the unique transcriptional and phenotypic sig-
natures of RUNX1mut BP-CML patients with aberrant
expression of lymphoid markers including CD19. Finally,
we demonstrated a potential role for the CAR T-cells
immunotherapy in addition to targeted therapy in RUNX1mut
BP-CML patients.
The incidence of RUNX1 mutations in BP-CML patients
ranges between 12.9 and 33.3%, varying with the cohort
size, disease phenotype (myeloid or lymphoid), and the
sequencing method used [22, 24, 27]. Recently in a large
BP-CML cohort [33], ABL1 and RUNX1 mutations were the
most common mutations. In our own discovery cohort, we
identified four mutations of RUNX1, that were located
within the Runt domain, in line with reports of BP-CML
and AML [11, 26, 27]. The identified variants have been
reported in AML, displaying variable effects on RUNX1
protein functions, including CBFB dimerization and DNA
binding, in addition to leukemia transformation [34]. In a
myeloid-BP patient, the RUNX1 mutation was the sole
leukemia-associated mutation identified both in CP (SNV)
and progression (SNV and LOH) samples. Giustacchini
et al. [35]. similarly reported a RUNX1 mutation in both CP
stem cells (SCs) and BP-SCs of a lymphoid-BP patient.
RUNX1mut CP-SCs demonstrate transcriptional similarities
with BP-SCs, rather than with RUNX1wt CP-SCs.
RUNX1 aberrations contribute to mutagenesis and
leukemic predisposition [36], and associate with down-
regulation of DNA repair genes in AML [37]. Likewise,
we demonstrated downregulation of DNA repair genes,
including CETN2 and MLH1, in RUNX1mut BP-CML. We
identified RAG-mediated recombination to be associated
with RUNX1mut. RUNX1 is important for RAG function in
early T-cell development [38]. Aberrant AID/RAG activity
is implicated in lymphoid malignancies, namely in ETV6-
RUNX1 ALL [8]. Our data revealed transcriptional upre-
gulation of several components of AID/RAG, which can
increase genetic vulnerability [39]. Leukemia cells from
RUNX1mut patients exhibited significant association with
AID/RAG-related SHM signature and enrichment of RAG-
RSS compared with cells from RUNX1wt patients. We
demonstrated presence of RAG off-target activity in an
IKZF1 deletion in RUNX1mut BP-CML, like previously
reported in Philadelphia-positive ALL (Ph-ALL) [40].
AID expression was suggested to contribute to lymphoid
progression in CML [41]. Recently, Thomson et al.
reported that RAG off-target activity plays a central
role in the progression of lymphoid-BP patients [42].
Interestingly, they reported a RUNX1mut myeloid-BP
patient with exceptionally high RAG expression and
aberrant lymphoid markers phenotype supporting the role
of RUNX1mut-induced RAG activity.
RUNX1mut BP-CML shares several genomic features
with RUNX1mut AML, underscoring similarity of RUNX1mut
across leukemias. RUNX1mut BP-CML exhibited other
mutations in BCORL1 and PHF6 genes, as well as IKZF1
deletions, comparable to the mutational landscape of
RUNX1mut AML [20, 21, 43]. In addition, upregulation of
early HSC signature, lymphoid markers, and various AML
prognostic markers in RUNX1mut BP-CML was another
similarity with RUNX1mut AML [44, 45]. Downregulation
of the coagulation pathway and megakaryocytic markers is
consistent with the role of RUNX1 mutations in FPD/AML
[46]. Furthermore, RUNX1mut BP-CML showed aberrant
expression of lymphoid antigens (CD19, CD7) in myeloid-
BP patients and overexpression of lymphoid TFs and
markers similar to RUNX1mut AML [47]. Aberrant expres-
sion of CD19 has been described in t(8;21)-AML to relate
with PAX5 overexpression [17]. We demonstrated over-
expression of PAX5 in RUNX1mut BP-CML patients, in
concord with data from RUNX1mut AML [48]. RUNX1mut
BP-CML patients showed upregulation of many pDC
markers. RUNX1 is a key TF in pDC development through
regulation of IRF8 [49]. A recently described AML entity,
“AML with pDC differentiation” [50], demonstrated
frequent RUNX1 mutations and expression of lymphoid
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antigens, comparable to RUNX1mut BP-CML. Noteworthy,
a study including 47 RUNX1mut-AML patients showed that
RUNX1mut blasts shared a common gene expression sig-
nature in contrast with RUNX1wt blasts, and transcriptional
differences between missense and nonsense RUNX1 muta-
tions were demonstrated in some RUNX1 target genes [45].
Further studies and analysis of recently published data [33]
will add to our understanding of mutation-specific-induced
transcriptional changes in BP-CML.
Development of new therapeutic options is essential for
management of BP-CML [51]. We identified potentially
useful targeted drugs for RUNX1mut BP-CML patients,
including mTOR inhibitors, glucocorticoids, VEGFR inhi-
bitors, and BCL2 inhibitors. VEGFR and mTOR inhibitors
are active in CBF-AML [52, 53]. Likewise, glucocorticoids
[45] and BCL2 inhibitors [54] showed inhibitory effects in
RUNX1mutAML, reflecting shared RUNX1mut signature. In
RUNX1mutAML, glucocorticoid sensitivity is associated
with RUNX1 mutations and wild-type RUNX1 activity [45],
which potentially explains variances in glucocorticoid
activity in our samples also. BET inhibitors that demon-
strate selective activity in RUNX1mut cell lines were recently
suggested as a targeted therapy for RUNX1mut AML [55].
Combination of imatinib with the selected drugs displayed
synergistic inhibition of RUNX1mut blasts, representing
promising treatment strategies for RUNX1mut BP-CML. A
strong evidence on the selective sensitivity of RUNX1mut
blasts was also demonstrated in our previous study where a
lymphoid-BP patient with a dominant RUNX1mut clone
(VAF:48%) received a DSRT-based VEGFR inhibitor axi-
tinib, which yielded clearance of the RUNX1mut clone at
relapse [25].
Our study also highlighted immunotherapy as an
effective approach for BP-CML management, especially
in RUNX1mut BP-CML patients with CD19 expression.
RUNX1 mutations are associated with upregulation of
several molecular targets for immunotherapy, including
CD19 [56] and CD133 [57]. CD19-CAR T-cell therapy
has been implemented in management of B-cell lympho-
mas, ALL, and Ph-ALL patients [58]. Combination of
CAR T cells with other immunotherapeutic approaches or
targeted therapies can further improve response rates to
CAR T cells treatment [59, 60]. We demonstrated a potent
ex vivo cytotoxic targeting of CD19-CAR T cells against
RUNX1mut BP-CML blasts in both myeloid-BP and
lymphoid-BP patients. In combination with imatinib,
CD19-CAR T cells showed enhanced killing of RUNX1mut
BP-CML blasts. CD19-CAR T cells successfully targeted
imatinib-resistant blasts, highlighting CD19-CAR T cells
as a potentially effective strategy in BP-CML specially
CD19-positive RUNX1mut BP-CML patients. The ther-
apeutic approach combining TKIs and CD19-CAR T cells
may also reduce the possibility of CD19-neg relapses,
previously encountered both with CD19 targeting anti-
bodies and CD19-CAR T cells in ALL [61, 62]. Inter-
estingly, recent case report described that CD19-CAR
T cells are able to induce remission in t(8;21) AML
patient [63] suggesting that in addition to BP-CML, this
therapy modality could be effective in other RUNX1mut
leukemia.
In conclusion, this study provides insights into the role of
RUNX1 mutations in CML progression by induced tran-
scriptional reprogramming and aberrant mutagenic AID/
RAG activity. Employing comprehensive phenotypic,
genetic, transcriptional, and drug sensitivity profiling data
highlighted multiple deregulated signaling pathways that
represent novel options for targeted therapy, and together
with CD19-CAR T-cell immunotherapeutic approach, may
provide a means to improve management of poor prognosis
BP-CML patients.
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